Effects of EpCAM overexpression on human breast cancer cell lines

Autor: Gilbert Spizzo, Marion Zitt, Oliver A. Wrulich, Florian Lehne, Martin Hermann, Sylvia Krobitsch, Guenther Gastl, Johanna M. Gostner, Agnieszka Martowicz, Dominic Fong
Jazyk: angličtina
Předmět:
Cancer Research
medicine.drug_class
Antineoplastic Agents
Breast Neoplasms
Cell Growth Processes
Docetaxel
Biology
Monoclonal antibody
lcsh:RC254-282
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Breast cancer
Antigen
Antigens
Neoplasm

Cell Movement
Surgical oncology
Cell Line
Tumor

medicine
Genetics
Humans
skin and connective tissue diseases
beta Catenin
030304 developmental biology
0303 health sciences
Microscopy
Confocal

Gene Expression Profiling
Cancer
Epithelial cell adhesion molecule
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Epithelial Cell Adhesion Molecule
medicine.disease
3. Good health
Wnt Proteins
chemistry
Oncology
030220 oncology & carcinogenesis
biology.protein
Cancer research
Female
Taxoids
Antibody
Cell Adhesion Molecules
Protein Processing
Post-Translational

Signal Transduction
Subcellular Fractions
Research Article
medicine.drug
Zdroj: BMC Cancer
BMC Cancer, Vol 11, Iss 1, p 45 (2011)
ISSN: 1471-2407
DOI: 10.1186/1471-2407-11-45
Popis: Background Recently, EpCAM has attracted major interest as a target for antibody- and vaccine-based cancer immunotherapies. In breast cancer, the EpCAM antigen is overexpressed in 30-40% of all cases and this increased expression correlates with poor prognosis. The use of EpCAM-specific monoclonal antibodies is a promising treatment approach in these patients. Methods In order to explore molecular changes following EpCAM overexpression, we investigated changes of the transcriptome upon EpCAM gene expression in commercially available human breast cancer cells lines Hs578T and MDA-MB-231. To assess cell proliferation, a tetrazolium salt based assay was performed. A TCF/LEF Reporter Kit was used to measure the transcriptional activity of the Wnt/β-catenin pathway. To evaluate the accumulation of β-catenin in the nucleus, a subcellular fractionation assay was performed. Results For the first time we could show that expression profiling data of EpCAM transfected cell lines Hs578TEpCAM and MDA-MB-231EpCAM indicate an association of EpCAM overexpression with the downregulation of the Wnt signaling inhibitors SFRP1 and TCF7L2. Confirmation of increased Wnt signaling was provided by a TCF/LEF reporter kit and by the finding of the nuclear accumulation of ß-catenin for MDA-MB-231EpCAM but not Hs578TEpCAM cells. In Hs578T cells, an increase of proliferation and chemosensitivity to Docetaxel was associated with EpCAM overexpression. Conclusions These data show a cell type dependent modification of Wnt signaling components after EpCAM overexpression in breast cancer cell lines, which results in marginal functional changes. Further investigations on the interaction of EpCAM with SFRP1 and TCF7L2 and on additional factors, which may be causal for changes upon EpCAM overexpression, will help to characterize unique molecular properties of EpCAM-positive breast cancer cells.
Databáze: OpenAIRE